{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:57:05Z","timestamp":1781308625995,"version":"3.54.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["USA-WA1\/2020"],"award-info":[{"award-number":["USA-WA1\/2020"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NR-52281"],"award-info":[{"award-number":["NR-52281"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA-GBW-GKISBBBB26982\/2024"],"award-info":[{"award-number":["CA-GBW-GKISBBBB26982\/2024"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["75A50123D00005"],"award-info":[{"award-number":["75A50123D00005"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007699","name":"University of Georgia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007699","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008872","name":"Asian Society for Pediatric Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008872","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.vaccine.2026.128490","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T22:34:50Z","timestamp":1774046090000},"page":"128490","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Intranasal PIV5-vectored SARS-COV-2 KP.2 vaccine protects against homologous and heterologous challenge in mice and hamsters"],"prefix":"10.1016","volume":"79","author":[{"given":"Kelsey","family":"Briggs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Gingerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Gingerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott K.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Phan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl A.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin D.","family":"Shepard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline K.","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah R.","family":"Hosking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nichole","family":"Orr-Burks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brytta K.","family":"Holloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Avella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Piotrowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"O\u2019boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bushra","family":"Wali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aayush","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehul S.","family":"Suthar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Tompkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric R.","family":"Lafontaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128490_bb0005","series-title":"U.S. Department of Health and Human Services C. COVID Data Tracker. Atlanta, GA","author":"Centers for Disease Control and Prevention","year":"2026"},{"key":"10.1016\/j.vaccine.2026.128490_bb0010","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41579-023-00878-2","article-title":"The evolution of SARS-CoV-2","volume":"21","author":"Markov","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2026.128490_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065944","article-title":"mRNA vaccines against SARS-CoV-2: advantages and caveats","volume":"24","author":"Echaide","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.vaccine.2026.128490_bb0020","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","article-title":"Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression","volume":"399","author":"Feikin","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128490_bb0025","article-title":"Rapidly declining SARS-CoV-2 antibody titers within 4 months after BNT162b2 vaccination","volume":"9","author":"Jo","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128490_bb0030","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/s41591-022-02162-x","article-title":"Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster","volume":"29","author":"Kurhade","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2026.128490_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/22221751.2021.2017757","article-title":"The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron","volume":"11","author":"Zhang","year":"2022","journal-title":"Emerg Microbes Infect"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128490_bb0040","doi-asserted-by":"crossref","DOI":"10.7326\/ANNALS-24-01015","article-title":"Effectiveness of the 2023-to-2024 XBB.1.5 COVID-19 vaccines over long-term follow-up\u202f: a target trial emulation","volume":"178","author":"Ioannou","year":"2025","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2026.128490_bb0045","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1080\/14760584.2022.2071705","article-title":"Repeated vaccination and \u2018vaccine exhaustion\u2019: relevance to the COVID-19 crisis","volume":"21","author":"Azim Majumder","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2026.128490_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.975980","article-title":"Evidence of exhausted lymphocytes after the third anti-SARS-CoV-2 vaccine dose in cancer patients","volume":"12","author":"Benitez Fuentes","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.vaccine.2026.128490_bb0055","article-title":"Evaluating a parainfluenza virus 5-based vaccine in a host with pre-existing immunity against parainfluenza virus 5","volume":"7","author":"Chen","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2026.128490_bb0060","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00554-20","article-title":"Single-dose, intranasal immunization with recombinant parainfluenza virus 5 expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) spike protein protects mice from fatal MERS-CoV infection","volume":"11","author":"Li","year":"2020","journal-title":"mBio"},{"key":"10.1016\/j.vaccine.2026.128490_bb0065","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1128\/JVI.02886-12","article-title":"A novel rabies vaccine based on a recombinant parainfluenza virus 5 expressing rabies virus glycoprotein","volume":"87","author":"Chen","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2026.128490_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2018.100002","article-title":"The autotransporter protein BatA is a protective antigen against lethal aerosol infection with Burkholderia mallei and Burkholderia pseudomallei","volume":"1","author":"Lafontaine","year":"2019","journal-title":"Vaccine X"},{"key":"10.1016\/j.vaccine.2026.128490_bb0075","article-title":"Efficacy of parainfluenza virus 5 (PIV5)-vectored intranasal COVID-19 vaccine as a single dose primer and booster against SARS-CoV-2 variants","volume":"99","author":"Beavis","year":"2025","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2026.128490_bb0080","doi-asserted-by":"crossref","first-page":"eadj7611","DOI":"10.1126\/sciadv.adj7611","article-title":"Intranasal parainfluenza virus type 5 (PIV5)-vectored RSV vaccine is safe and immunogenic in healthy adults in a phase 1 clinical study","volume":"9","author":"Spearman","year":"2023","journal-title":"Sci Adv"},{"key":"10.1016\/j.vaccine.2026.128490_bb0085","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adw0896","article-title":"Safety and immunogenicity of intranasal parainfluenza virus type 5 (PIV5)\u2013vectored COVID-19 vaccine in adults and teens in an open-label phase 1 trial","volume":"11","author":"Spearman","year":"2025","journal-title":"Sci Adv"},{"key":"10.1016\/j.vaccine.2026.128490_bb0090","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abi5246","article-title":"Protection of K18-hACE2 mice and ferrets against SARS-CoV-2 challenge by a single-dose mucosal immunization with a parainfluenza virus 5\u2013based COVID-19 vaccine","volume":"7","author":"An","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.vaccine.2026.128490_bb0095","article-title":"A parainfluenza virus 5 (PIV5)-vectored intranasal SARS-CoV-2 vaccine (CVXGA1) elicits protective and long-lasting immunity in nonhuman primates","volume":"0","author":"Beavis","year":"2026","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2026.128490_bb0100","series-title":"COVID-19","author":"CDC","year":"2024"},{"key":"10.1016\/j.vaccine.2026.128490_bb0105","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s44298-023-00007-z","article-title":"Evolutionary trajectory of SARS-CoV-2 genome shifts during widespread vaccination and emergence of Omicron variant","volume":"1","author":"Gayvert","year":"2023","journal-title":"npj Viruses"},{"key":"10.1016\/j.vaccine.2026.128490_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2022.01.015","article-title":"SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron","volume":"185","author":"Tarke","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2026.128490_bb0115","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-65896-5","article-title":"Immunologic and biophysical features of the BNT162b2 JN.1- and KP.2-adapted COVID-19 vaccines","volume":"16","author":"Chen","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2026.128490_bb0120","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1093\/cid\/ciaa325","article-title":"Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in a Golden Syrian Hamster model: implications for disease pathogenesis and transmissibility","volume":"71","author":"Chan","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128490_bb0125","article-title":"Reduced pathogenicity of the SARS-CoV-2 Omicron variant in hamsters","volume":"3","author":"McMahan","year":"2022","journal-title":"Med (N Y)"},{"key":"10.1016\/j.vaccine.2026.128490_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102054","article-title":"Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model","volume":"24","author":"Mohandas","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.vaccine.2026.128490_bb0135","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s42003-022-03171-9","article-title":"The SARS-CoV-2 Alpha variant exhibits comparable fitness to the D614G strain in a Syrian hamster model","volume":"5","author":"Cochin","year":"2022","journal-title":"Commun Biol"},{"key":"10.1016\/j.vaccine.2026.128490_bb0140","article-title":"Efficacy of a parainfluenza virus 5 (PIV5)-based H7N9 vaccine in mice and guinea pigs: antibody titer towards HA was not a good indicator for protection","volume":"10","author":"Li","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2026.128490_bb0145","doi-asserted-by":"crossref","first-page":"5985","DOI":"10.1128\/JVI.00120-13","article-title":"Single-dose vaccination of a recombinant parainfluenza virus 5 expressing NP from H5N1 virus provides broad immunity against influenza a viruses","volume":"87","author":"Li","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2026.128490_bb0150","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1128\/JVI.02330-12","article-title":"Recombinant parainfluenza virus 5 vaccine encoding the influenza virus hemagglutinin protects against H5N1 highly pathogenic avian influenza virus infection following intranasal or intramuscular vaccination of BALB\/c mice","volume":"87","author":"Mooney","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2026.128490_bb0155","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.623996","article-title":"Parainfluenza virus 5 priming followed by SIV\/HIV virus-like-particle boosting induces potent and durable immune responses in nonhuman Primates","volume":"12","author":"Xiao","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128490_bb0160","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/infdis\/jir436","article-title":"Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children","volume":"204","author":"Hoft","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128490_bb0165","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00414-16","article-title":"Comparisons of the humoral and cellular immune responses induced by live attenuated influenza vaccine and inactivated influenza vaccine in adults","volume":"24","author":"Hoft","year":"2017","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2026.128490_bb0170","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41564-024-01903-7","article-title":"Vaccine-induced T cell responses control Orthoflavivirus challenge infection without neutralizing antibodies in humans","volume":"10","author":"Kalimuddin","year":"2025","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.vaccine.2026.128490_bb0175","first-page":"601","article-title":"Estimates of SARS-CoV-2 seroprevalence and incidence of primary SARS-CoV-2 infections among blood donors, by COVID-19 vaccination status \u2014 United States, April 2021\u2013September 2022","author":"Jefferson","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2026.128490_bb0180","first-page":"1526","article-title":"Effectiveness of bivalent mRNA vaccines in preventing symptomatic SARS-CoV-2 infection \u2014 increasing community access to testing program, United States, September\u2013November 2022. In: CDC, editor","volume":"2022;71","author":"Ruth Link-Gelles PAAC, PhD1,2; Katherine E. Fleming-Dutra, MD1; Zachary R. Smith, MA3; Amadea Britton, MD1; Ryan E. Wiegand, PhD1; Joseph D. Miller, PhD3; Emma K. Accorsi, PhD1,4; Stephanie J. Schrag, DPhil1; Jennifer R. Verani, MD1; Nong Shang, PhD1; Gordana Derado, PhD1; Tamara Pilishvili, PhD1","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2026.128490_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003992","article-title":"Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: a nationwide Danish cohort study","volume":"19","author":"Gram","year":"2022","journal-title":"PLoS Med"},{"issue":"Pt 11","key":"10.1016\/j.vaccine.2026.128490_bb0190","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1099\/0022-1317-68-11-2769","article-title":"Isolation and characterization of monoclonal antibodies to simian virus 5 and their use in revealing antigenic differences between human, canine and simian isolates","volume":"68","author":"Randall","year":"1987","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2026.128490_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2021.03.009","article-title":"Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant","volume":"29","author":"Edara","year":"2021","journal-title":"Cell Host Microbe"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26002987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26002987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:48:35Z","timestamp":1781308115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26002987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":39,"alternative-id":["S0264410X26002987"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128490","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intranasal PIV5-vectored SARS-COV-2 KP.2 vaccine protects against homologous and heterologous challenge in mice and hamsters","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128490","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128490"}}